However, subjects with synucleinopathies or with AD presented a wider PrP immunoreactivity than subjects with a normal neuropathological examination and a history of T2DM (p < 0.0001 for synucleinopathies and p = 0.0012 for AD subjects) or controls (p < 0.0001 for synucleinopathies and AD subjects). This evidence concerns the gene PRNP and synucleinopathy.